In a phase 1 study combining PD-1 blockade (nivolumab) with either an anti-CTLA-4 antibody (ipilimumab) or anti-KIR antibody (lirilumab) resulted in an ORR of 9-22% in patients with NHL, and toxicity from the combinations was greater than that seen with the single agents alone [57]. Here, CTLA4 is linked to non-Hodgkin lymphoma.